Objective: The aim of this study was to evaluate the impact of STN DBS on the changes of UPDRS scale and RS parameters (OFF phase) in 3 PD groups: early-DBS STN (DBS-group), late-DBS STN (POP-group) and one that obtained only medication therapy (MED-group).

Background: Subthalamic nucleus deep brain stimulation (STN DBS) has been claimed to change the progression in animal models, but there are lacking information about the possible neuromodulative role of STN DBS in humans.  

Methods: DBS-group consisted of 20 PD patients (7F,13M) who underwent bilateral STN DBS. POP-group consisted of 15 post-DBS PD patients (6F,9M) in median 24 month-time after surgery. Control group (MED-group) consisted of 24 patients (13F,11M) who did not underwent surgical intervention. UPDRS III scale and RS parameters (latency, amplitude, duration, peak of velocity) were measured during 3 visits (V1, V2, V3) in total OFF phase. The mean period between visits was 9±3months.

Results: We have observed the comparable UPDRS III gain in V3/V2/V1 MED-group and POP-group (p<0,05) but not V3/V2 (p>0,05) vs V2/V1 (p<0,05) DBS-group. There was also interesting relation between RS latency and DBS treatment: the only change in V2/V1 DBS-group vs no change in MED-group and POP-group (p>0,05).

Conclusions: The strongest effect of STN DBS on RS parameters was during first 6 postoperative months whereas the most influential effect of STN DBS treatment on UPDRS III OFF score was observed during 6-12 months after surgery (but not in longer post-DBS periods).   

References: Partially supported by grant: NCN Dec-2011/03/B/ST6/03816.

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/updrs-iii-score-and-rs-latency-can-determine-the-possible-neuromodulative-role-of-stn-dbs-in-parkinsons-disease-pd-patients/